Dr. Charles Magness was the principal founder of KPI Therapeutics in 2013 and is currently the President and Chief Executive Officer. He is responsible for strategy and execution of all corporate initiatives, development opportunities and acquisition of capital. Previously, he was President and Chief Executive Officer for Kineta, Inc. which he cofounded in 2007. Under his leadership, Kineta moved rapidly to acquire and finance its lead autoimmune program and advance its discovery stage antiviral research. Dr. Magness secured several significant investment partnerships. As a founder, he also developed and successfully implemented Kineta's business model which is designed to reduce investor risk and provide faster returns on investment. Dr. Magness, along with Kineta co-founder, Dr. Shawn Iadonato, founded Illumigen Biosciences, Inc. in 2000. Serving initially as CIO and then President and COO from 2002-2007, Dr. Magness led that company from inception to acquisition by Cubist Pharmaceuticals. During his tenure, Illumigen raised over $23M through financing and business development activities, contract revenue, and grants. At Illumigen, he also was responsible for investor relations, intellectual property licensing and legal affairs. Prior to founding Illumigen, he managed sequence data analysis for the University of Washington Genome Center and co-developed SEGMAP, a widely used tool essential for mapping the human genome. Dr. Magness has more than 25 years’ experience developing and managing statistical solutions for large scientific projects. He received a Research Career Award from the National Institutes of Health for his transition into human genomics from his formal training in mechanical and aerospace engineering. After earning his B.S., M.S., and Ph.D. degrees from Lehigh University, he was a Research Scientist at McDonnell Douglas Research Labs. He is co-inventor on multiple issued US and international patents and was awarded an official commendation when employed by the US Army.
Mr. Philips has over 25 years of pharmaceutical experience in the US and overseas with large, intermediate and start-up companies. His extensive career includes experience with development and commercialization of both small molecules and biologic agents in a variety of sectors including: oncology, autoimmune diseases, cardiovascular disorders, viral diseases, dermatology and others. He spent the early part of his career with Bristol Myers and held senior positions at both Schering Plough (now Merck), and Bayer Schering Pharmaceuticals. He was President at Cell Therapeutics, a company focused on new cancer therapies. In 2012 he accepted an invitation to serve as Entrepreneur-in-Residence at the University of Washington. He works with staff and faculty to advance the spinout and licensing of life science and emerging technology platforms. Mr. Philips has broad industry experience and an extensive record in lifecycle management, commercialization of new drugs, and business development and partnership management. He received a BSBA and MBA from Ohio State University. He has been actively involved in pharmaceutical industry organizations in the US and overseas and served as a board member to the leading industry organizations in Canada, Thailand and Australia.
Gary is a serial entrepreneur and has over thirty years of experience in corporate development, finance, operations, project management, sales, marketing and personnel management. His career background includes new business venture startup, capital formation, operational/financial growth and corporate development in the high technology, solar energy and real estate development industry sectors. Early in his career he led award winning engineering teams for Fortune 100 companies such as Cisco Systems with vertical market responsibility for North, South and Latin America. During his tenure at Cisco Systems he built and developed strategic business relationships with the executive management of Fortune 100/500 accounts, channel partners and systems integrators. Gary formerly served as the Director of Corporate Development at Kineta, Inc. and before that as the former VP of Operations and Business Development at SolarUniverse Mission Bay. He is also the Chief Executive Officer and Founder of the Northridge Development Group and he is on the Steering Committee for Medical Teams International.
Dr. Olsen is the head of scientific affairs for KPI Therapeutics, overseeing all aspects of the research, development, and clinical advancement for each of the programs. She manages the external collaborations, outsourced activities, and scientific rationale for advancing the drug candidates focused on autoimmune diseases. Dr. Olsen has over 15 years of research experience in drug discovery and development. She graduated summa cum laude with a degree in Microbiology and received a Ph.D. in Molecular and Cellular Biology from Oregon State University. Dr. Olsen has authored or co-authored 30 peer-reviewed research publications, is a co-inventor on nine U.S. patents, and has 61 abstracts presented at national and international scientific meetings. Her work has led to seven funded research grants and contracts focused on the identification and development of novel antiviral therapies. Prior to KPI, Dr. Olsen was the Director for Alliance Management at Kineta, a sister company to KPI, where she was involved with the autoimmune, antiviral, and vaccine adjuvant programs. Before Kineta, Dr. Olsen led an antiviral drug discovery and development program at SIGA Technologies with a focus on flavivirus and poxvirus drug development.
Molly Dorr is the Sr. Director of Operations and Human Resources for KPI Therapeutics and oversees the business needs and requirements of the organization. Mrs. Dorr has over 20 years of experience in high-growth and emerging companies in various industries including Technology, Telecom, Manufacturing and Consulting. She has worked for Fortune 500 companies as well as start-ups to support organizational, operational and personnel needs. Mrs. Dorr is a graduate of Oregon State University with a B.S. degree in Communications and also attended University of Lancaster in England.
Ryan is responsible for business development research for the various drug programs along with working on the corporate development team. Prior to working at KPI, he worked at Daiichi Sankyo as part of their Commercial Leadership Development Program on the Sales Operations team. There he helped to create tools to better implement managed markets data into the company’s sales strategies along with analyzing and reporting regional prescription data in support of the 1500+ sales representatives. He's also previously worked at KPI's development partner Kineta on the business development team. Ryan received his B.S. in Biology from Duke University.
Daniela is KPI’s Clinical Development and Operations Coordinator. Her key focus is on providing competitive intelligence including integrating existing databases and published literature for disease and product areas of interest as well as providing alliance management for external research collaborations. In addition to her role in clinical development, she provides operational and business support to KPI. Prior to KPI, Daniela worked as a research assistant at several UW laboratories and the National Oceanic and Atmospheric Administration. Daniela received her B.S. in Biology from the University of Washington.
With more than 25 years of experience as a Chief Financial Officer, Don understands the steps that need to be taken when companies are preparing for a strategic transaction. He works with the investors, Board Members, and CEOs to assess any issues and create a plan to move forward. Works with current Finance Teams to improve their skills and knowledge.
Raj has a great understanding of the obstacles a small biotech company can face when trying to move to large product development. He has over 20 years of CMC and manufacturing experience at companies like Adler where he was the Vice President of Pharmaceutical Operations. In his years in the industry he has also secured numerous patents.
Mr. Eramian is responsible for providing communications to KPI's investors and external constituencies. He has over 20 years of experience in developing communication and investor programs in the biotechnology industry. He is Co-Founder of Opus Biotech Communications specializing in building communications and investor programs for emerging life sciences companies. Previously he was Senior Vice President for Communications & Investor Relations for Kineta, Inc. and also Executive Vice President of Communications and Investor Relations at Cell Therapeutics. Mr. Eramian was the first Vice President of Communications for the Biotechnology Industry Organization (BIO) in Washington DC. Mr. Eramian has served as Director of Public Affairs for the U.S. Department of Justice and the spokesman for the Attorney General of the United States. He was also Assistant Administrator for Public Affairs at the U.S. Small Business Administration which included its technology development programs. In addition Mr. Eramian was as a Chief of Staff in the Massachusetts State Senate and was previously Executive Editor of Suburban World Newspapers also in Massachusetts, He holds a BA in English Literature UMass-Amherst and MPA from Suffolk University.
Former Vice President of Clinical Research and Development at Immunex and Amgen where he worked on clinical development of ENBREL®. He later went to work as the Senior Vice President and Chief Medical Officer at Trubion. He was also a former practicing rheumatologist.
With many years in Regulatory Affairs he has gained an extensive knowledge of US and EMA health authorities. Working with companies like Amgen where he was the Global Regulatory Team leading. He was also the Vice President of Regulatory Affairs at Velcura Therapeutics Inc., and Cell Therapeutics.